We are live on ! Find out more
A

Abingworth Portfolio holdings

AUM $307M
1-Year Est. Return 93.47%
This Fund
S&P 500
This Quarter Est. Return
+38.67%
1 Year Est. Return
+93.47%
3 Year Est. Return
+184.38%
5 Year Est. Return
+342.7%
10 Year Est. Return
–
AUM
$358M
AUM Growth
+$207M
Cap. Flow
+$140M
Cap. Flow %
39.28%
Top 10 Hldgs %
97.5%
Holding
17
New
1
Increased
1
Reduced
1
Closed
1

Top Buys

Rank Stock Value
1
PCVX icon
Vaxcyte
PCVX
+$134M
2
SLNO
Soleno Therapeutics
SLNO
+$9.63M

Top Sells

Rank Stock Value
1
TARA icon
Protara Therapeutics
TARA
+$1.87M
2
CHMA
Chiasma, Inc. Common Stock
CHMA
+$1.35M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PCVX icon
1
Vaxcyte
PCVX
$8.01B
$132M 36.77%
+4,168,718
New +$134M
PSNL icon
2
Personalis
PSNL
$1.4B
$70.6M 19.75%
5,449,294
– –
PHAT icon
3
Phathom Pharmaceuticals
PHAT
$849M
$39.4M 11.01%
1,203,135
– –
CRSP icon
4
CRISPR Therapeutics
CRSP
$4.63B
$38.1M 10.64%
519,198
– –
SLNO
5
DELISTED
Soleno Therapeutics
SLNO
$22.8M 6.37%
686,840
+222,222
+48% +$9.63M
XCUR icon
6
Exicure
XCUR
$12M
$17M 4.74%
46,513
– –
SRRA
7
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
$10.5M 2.95%
876,541
– –
SIEN
8
DELISTED
Sientra, Inc.
SIEN
$9.23M 2.58%
239,084
– –
PRTK
9
DELISTED
Paratek Pharmaceuticals, Inc.
PRTK
$5.42M 1.52%
1,041,131
– –
VRNA
10
DELISTED
Verona Pharma
VRNA
$4.22M 1.18%
901,943
– –
TARA icon
11
Protara Therapeutics
TARA
$229M
$3M 0.84%
53,612
-60,307
-53% -$1.87M
MTEM
12
DELISTED
Molecular Templates, Inc.
MTEM
$2.76M 0.77%
13,333
– –
SYRE icon
13
Spyre Therapeutics
SYRE
$8.45B
$2.22M 0.62%
9,620
– –
OBSV
14
DELISTED
ObsEva SA Ordinary Shares
OBSV
$517K 0.14%
87,999
– –
CBAY
15
DELISTED
Cymabay Therapeutics
CBAY
$456K 0.13%
131,036
– –
OCGN icon
16
Ocugen
OCGN
$450M
$2K ﹤0.01%
7,111
– –
CHMA
17
DELISTED
Chiasma, Inc. Common Stock
CHMA
– –
-370,671
Closed -$1.35M

Similar funds

AAM
Arabesque Asset Management London, United Kingdom $296M AUM 15.19% 1-Year Est. Return
EP
Equius Partners Novato, California $324M AUM 8.27% 1-Year Est. Return
LDFR
Lehman & Derafelo Financial Resources Media, Pennsylvania $337M AUM 8.16% 1-Year Est. Return
MPAM
Monarch Partners Asset Management Boston, Massachusetts $339M AUM 2.52% 1-Year Est. Return
MAG
Mass Ave Global New York $342M AUM 20.58% 1-Year Est. Return
CDIA
Capital Directions Investment Advisors Atlanta, Georgia $268M AUM 20.15% 1-Year Est. Return
GTCM
Gyon Technologies Capital Management Denville, New Jersey $267M AUM 11.62% 1-Year Est. Return
ACMV
August Capital Management VII Palo Alto, California $265M AUM 26.86% 1-Year Est. Return

Abingworth's Q2 2020 Portfolio in Review

As of Q2 2020, Abingworth held 17 positions worth $358M, up 138% from $151M the previous quarter. Its ten largest holdings account for 97% of the portfolio.

Abingworth deployed $140M of net new capital in Q2 2020, opening 1 new position and adding to 1 existing holding. Its largest new stake was Vaxcyte: 4,168,718 shares worth $132M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

On the sell side, the largest reduction was Protara Therapeutics, an estimated $1.87M trimmed.

  • Abingworth's largest Q2 2020 buy was Vaxcyte: 4,168,718 shares worth $132M.
  • Abingworth added most to Soleno Therapeutics in Q2 2020, an estimated $9.63M increase.
  • Abingworth's biggest Q2 2020 reduction was Protara Therapeutics, cutting an estimated $1.87M.
  • Abingworth fully exited Chiasma, Inc. Common Stock in Q2 2020, selling an estimated $1.35M.
  • Abingworth's ten largest holdings make up 97% of its $358M portfolio in Q2 2020.
  • Abingworth opened 1 new position and closed 1 in Q2 2020.
  • Abingworth's portfolio value rose 138% quarter-over-quarter to $358M.

Based on Abingworth's 13F filing for Q2 2020, filed 14 Aug 2020.